Session » Antiphospholipid Syndrome

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 1724

Pandemic Influenza Immunization in Primary Antiphospholipid Syndrome (PAPS): A Trigger to Autoantibody Production?

Abstract Number: 1725

ANTI-Factor Xa Antibodies ARE Significantly Increased in Patients with Systemic LUPUS Erythematosus and Antiphospholipid Syndrome

Abstract Number: 1726

Lack of Correlation Between Mannose-Binding Lectin Gene Polymorphisms and the Thickness of the Carotid Artery Intima-Media (IMT) in Primary Antiphspholipid Syndrome

Abstract Number: 1727

Affinity Purified Antibodies Directed to Domain I of β2GPI Are Pathogenic in a Mouse Model of Thrombosis

Abstract Number: 1728

Purified IgG From Antiphospholipid Syndrome Patients with Pregnancy Morbidity Alone Inhibit Trophoblast Migration and Activate a TLR4 MyD88 Independent Pathway

Abstract Number: 1729

Ribophorin II Is Involved in the Tissue Factor Expression Mediated by Phosphatidylserine-Dependent Antiprothrombin Antibody On Monocytes

Abstract Number: 1730

Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus

Abstract Number: 1731

IgA Anti-β₂glycoprotein I Antibodies Are Pathogenic in a Mouse Model of APS

Abstract Number: 1732

Annexin A5 Resistance Identifies a Subset of Thrombosis Patients in Systemic Lupus Erythematosus

Abstract Number: 1733

Effect of Hydroxychloroquine (HCQ) On the Annexin A5 Resistance Assay (AnxA5-RA) in Antiphospholipid Antibody (aPL)-Positive Patients: Preliminary Results of an Ongoing Prospective Study

Abstract Number: 1734

Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities

Abstract Number: 1735

Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)

Abstract Number: 1736

The Estimated Prevalence of Antiphospholipid Antibodies in the General Population with Pregnancy Morbidity

Abstract Number: 1737

Diffuse Alveolar Hemorrhage Caused by Primary Antiphospholipid Syndrome

Abstract Number: 1738

Myocardial Dysfunction and Valvulopathy Worsens with Time in Patients with Antiphospholipid Syndrome: A 10-Year Follow-up Study

Abstract Number: 1740

Impairment of Quality of Life in Patients with Antiphospholipid Syndrome

Abstract Number: 2455

Establishment of Standardized International Units for IgG Anti-β₂glycoprotein Antibody Measurement

Abstract Number: 2456

Pro-Inflammatory and Pro-Thrombotic Markers in Persistently Antiphospholipid Antibody-Positive Patients with/without Systemic Lupus Erythematosus

Abstract Number: 2457

An Open-Label Prospective Pilot Mechanistic Study of Fluvastatin in Persistently Antiphospholipid Antibody-Positive Patients

Abstract Number: 2458

The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infarction, and Deep Vein Thrombosis

Abstract Number: 2459

Efficacy of Aspirin for the Prevention of the First Thrombo-Embolic Events in Patients with Antiphospholipid Antibodies: A Metanalysis of Literature Data

Abstract Number: 2460

Dual Antiplatelet Therapy As Prophylaxis of Recurrent Arterial Thrombosis in Patients with　antiphospholipid Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.